Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner (Q85055261)
Jump to navigation
Jump to search
scientific article published on 07 December 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner |
scientific article published on 07 December 2009 |
Statements
Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner (English)
Liat Izhak
Gizi Wildbaum
Uri Weinberg
Yuval Shaked
Jennifer Alami
Daniel Dumont
Boris Friedman
Avi Stein
7 December 2009